Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
GILD logo

Gilead Profits Rebound to $8.5 Billion as HIV Sales Hit $20.8 Billion

GILD10-KFiling Date: 2/24/2026
Gilead Sciences, Inc.
Description

What this story covers

Gilead Sciences demonstrated a strong 2025 recovery, with net income surging to $8.5 billion. Growth was driven by a $20.8 billion HIV franchise and strategic oncology pivots, successfully offsetting a 49% decline in pandemic-related Veklury sales.

Story snapshot

CompanyGilead Sciences, Inc.
TickerGILD
VariantStandard detailed
Duration12:59
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000882095-26-000006
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in